This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kurokawa, K. Articles by Ogawa, N. Search for Related Content PubMed PubMed Citation Articles by Kurokawa, K. Articles by Ogawa, N. Social Bookmarking                         What's this?

Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis

Department of Internal Medicine V, School of Medicine, Tokai University, Isehara, Kanagawa, Japan, kurokawa@ is.icc.u-tokai.ac.jp

Keishi Abe

Division of Internal Medicine, Sendai Social Insurance Hospital, Sendai, Miyagi, Japan

Takao Saruta

Department of Internal Medicine, School of Medicine, Keio University, Shinjuku, Tokyo, Japan

Masaaki Arakawa

Department of Internal Medicine , Niigata University School of Medicine, Niigata, Niigata, Japan

Ryuichi Kikkawa

Department of Internal Medicine , Shiga University of Medical Science, Ohtsu, Shiga, Japan

Naohiko Ueda

Nara Institute of Science and Technology Healthcare Center, Ikoma, Nara, Japan

Kaoru Onoyama

Division of Internal Medicine, Nippon Steel Yawata Memorial Hospital, Kita-Kyushu, Fukuoka, Japan

Kimio Tomita

Division of Internal Medicine, Sendai Social Insurance Hospital, Sendai, Miyagi, Japan

Nobuya Ogawa

Ehime University, Matsuyama, Ehime, Japan

A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis. Patients (n=280) were treated for 12 weeks with candesartan cilexetil 2, 4, or 8 mg given orally once-daily (o.d.). The improvement in urinary protein excretion observed at the end of the treatment period was 15.9% in the 2 mg group, 25.6% in the 4 mg group, and 34.6% in the 8 mg group, respectively, showing a clear dose-response (2 mg <4 mg <8 mg; p=0.003). The mean reduction in urinary protein excretion was 11.3% in the 2 mg group, 26.3% in the 4 mg group, and 26.0% in the 8 mg group, showing a dose-response pattern, in that the effect of 4 mg and 8 mg was greater than that of 2 mg (2 mg <4 mg ~8 mg; p=0.010). As the observed reduction in urinary protein excretion failed to correlate with changes in mean blood pressure, it could not be attributed to the antihypertensive effect of the study drug alone. This suggests that candesartan cilexetil, 4—8 mg o.d., has antiproteinuric effects in patients with chronic glomerulonephritis.

Key Words: candesartan cilexetil • glomerulonephritis • antiproteinuric effect • prospective randomised clinical trial

References

• Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.[Abstract/Free Full Text]
• The GISEN group: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
• Arakawa K., OgiwaraT, Iimura K. et al. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension - A double-blind, parallel group-comparison study using enalapril maleate as control drug-. Rinshou Iyaku 1998;14:871-918.
• Shibouta Y., Inada Y., Ojima M. et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+)-1-(cyclohexyl-oxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1Htetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-20.[Abstract/Free Full Text]
• Noda M., Shibouta Y., Inada Y. et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new non-peptide AII antagonist. Biochem Pharmacol 1993;46:311-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fujishima M., Hiyama K., Eto S. et al. Pharmacokinetic study of candesartan cilexetil, a novel angiotensin II receptor antagonist, in patients with renal impairment. Rinshou Iyaku 1996;12:3333-52.
• Urata H., Kinoshita A., Perez DM et al. Cloning of the gene and complementary DNA for human heart chymase. J Biol Chem 1991;266:17173-9.[Abstract/Free Full Text]
• Tojo S., Honda N., Shibata A. et al. Clinical evaluation of AS-05 (Dilazep) in chronic glomerulonephritis - Nationwide multicenter concurrent double-blind comparative study. Kidney Dial 1986;20:289-313 (Japanese).
• Etsugawa S., Sato M., Narita M., Sakai N., Nakajima M. Clinical evaluation of an immunosuppressive drug, mizoribine (HE-69) on steroid-resistant nephrotic syndrome-A multicenter double-blind comparison study with placebo-. Kidney Dial 1993;34:631-50 (Japanese).
• Inada Y., Wada T., Shibouta Y. et al. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, ( )-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 1994;268:1540-7.[Abstract/Free Full Text]
• Ito K., Imanishi M., Kito G. Comparison of the hypotensive effects of TCV-116 and losartan in chronic renal hypertensive dogs.Jpn Pharmacol Ther 1996;24:2227-33.
• Ito K., Shiomi M., Kito G. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 1995;18:69-75.[Medline] [Order article via Infotrieve]
• Noda M., Matsuo T., Fukuda R. et al. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999;56:898-909.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ohta M., Nagano H., Noda M. et al. Blockade of reninangiotensin system ameliorates renal injury in NIDDM model rats. Clin Exp Nephrol 2000;4:207-14.[CrossRef]
• Noda M., Matsuo T., Nagano-Tsuge H. et al. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats). Jpn J Pharmacol 2001;85:416-22.[CrossRef][Medline] [Order article via Infotrieve]
• Tojo S., Narita M., Hatano M. et al.A double blind controlled study of dipyridamole-perlongets and placebo in patients with chronic glomerulonephritis-multi-clinical study. Kidney Dial 1987;22:751-76 (Japanese).

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 3, 167-175 (2002)
DOI: 10.3317/jraas.2002.037


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kurokawa, K. Articles by Ogawa, N. Search for Related Content PubMed PubMed Citation Articles by Kurokawa, K. Articles by Ogawa, N. Social Bookmarking                         What's this?